Affiliation:
1. Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA 02115, United States
Abstract
Transplantation is the only cure for end-stage organ failure. Current immunosuppressive
drugs have two major limitations: 1) non antigen specificity, which increases the risk of cancer and
infection diseases, and 2) chronic toxicity. Cell therapy appears to be an innovative and promising
strategy to minimize the use of immunosuppression in transplantation and to improve long-term graft
survival. Preclinical studies have shown efficacy and safety of using various suppressor cells, such as
regulatory T cells, regulatory B cells and tolerogenic dendritic cells. Recent clinical trials using cellbased
therapies in solid organ transplantation also hold out the promise of improving efficacy. In this
review, we will briefly go over the rejection process, current immunosuppressive drugs, and the potential
therapeutic use of regulatory cells in transplantation.
Publisher
Bentham Science Publishers Ltd.
Subject
Genetics(clinical),Drug Discovery,Genetics,Molecular Biology,Molecular Medicine
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献